The first few days of the year are usually quiet. Fewer launches, fewer declarations, more space to take stock. I’ve come to appreciate this pause. It’s often when patterns surface not because they’re ...

Vericel's future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. Read ...